{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-000578","form_type":"8-K","ticker":"PRPH","cik":"0000868278","company_name":"ProPhase Labs, Inc.","filed_at":"2024-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.091592+00:00","generated_at":"2026-06-07T04:24:38.835170+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ProPhase Labs appoints Jed Latkin as COO; CFO Robert Morse returns to Controller role","bullets":["Jed Latkin named COO effective Jan 1, 2024; base salary $350,000, sign-on bonus $80,000.","Latkin receives inducement stock options for 500,000 shares at $6.00, vesting over 3 years (25% immediate).","Robert Morse ceases as CFO and resumes Controller role effective Jan 1, 2024, reporting to COO.","Press release highlights 2024 growth plans for Nebula Genomics, Pharmaloz Manufacturing, and BE-SMART test commercialization.","Latkin previously served as CEO of Navidea and has 28+ years in finance and biotech."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-000578","json":"https://secwatch.observer/filing/0001493152-24-000578.json","markdown":"https://secwatch.observer/filing/0001493152-24-000578.md","text":"https://secwatch.observer/filing/0001493152-24-000578.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/868278/000149315224000578/0001493152-24-000578-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/868278/000149315224000578/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:24:38.835170+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b2536ccfcd","claim":"Robert A. Morse changed role as Controller at ProPhase Labs, Inc..","evidence_excerpt":"Robert A. Morse mutually agreed that Mr. Morse would cease to be Chief Financial Officer of the Company and resume his role as Controller of the Company, effective January 1, 2024,","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/868278/000149315224000578/0001493152-24-000578-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased as CFO and resumed as Controller"},{"label":"Role","value":"Controller"}],"fact_type":"executive_change"},{"claim_id":"d223dfdf90","claim":"Jed A. Latkin was appointed as Chief Operating Officer at ProPhase Labs, Inc..","evidence_excerpt":"Jed A. Latkin has been appointed to serve as Chief Operating Officer of the Company, effective on January 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/868278/000149315224000578/0001493152-24-000578-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}